Wilson M E
Yerkes Primate Research Center of Emory University, Lawrenceville, Georgia 30043, USA.
J Clin Endocrinol Metab. 1998 Jun;83(6):2018-28. doi: 10.1210/jcem.83.6.4872.
Developmental changes in the GH-insulin-like growth factor I (IGF-I) axis were evaluated in female rhesus monkeys to test the hypothesis that estradiol differentially regulates IGF-I secretion and molar ratios of IGF-I to IGF-binding protein-3 (IGFBP-3) from adolescence into adulthood and that estradiol can reestablish GH secretion in the face of enhanced IGF-I negative feedback inhibition of GH. Adult ovariectomized females were compared to ovariectomized adolescent females studied from 18-36 months of age, a period encompassing the juvenile phase through the expected age at first ovulation. A subgroup of adult (n = 5) and adolescent females (n = 5) was treated continuously with human IGF-I (110 micrograms/kg.day, s.c.) throughout the study period and were compared to age-matched, untreated adults (n = 5) and adolescent animals (n = 6). To further understand how IGF-I affects the GH-IGF-I axis, the acute response to IGF-I (100 micrograms/kg, s.c.) was assessed in adults and at two ages in developing females. Furthermore, all females were treated periodically with estradiol (4 micrograms/kg.day) to assess the effects on the parameters of the GH-IGF-I axis from adolescence into adulthood. Finally, the response to GHRH (1.0 microgram/kg, i.v.) was assessed in adult females and in adolescent females at 18 and 24 months during no estradiol and estradiol replacement. Serum IGF-I and IGFBP-3, in the absence of estradiol replacement, increased significantly throughout puberty before declining from late adolescence into adulthood. Supplementation with IGF-I resulted in a significant increase in both serum IGF-I and IGFBP-3 concentrations at all ages, although the effect was less in juvenile females. Nevertheless, the age-dependent increase and decline in IGF-I and IGFBP-3 were maintained in these supplemented animals. Estradiol replacement significantly increased both serum IGF-I and IGFBP-3 through adolescence, even in IGF-I-supplemented animals. However, with the transition from adolescence, estradiol suppressed serum IGF-I secretion, yet continued to increase IGFBP-3 in young adult and fully adult females. This change in proportionately less IGF-I compared with IGFBP-3 resulted in a significant age-dependent decrease in the molar ratio of IGF-I to IGFBP-3. Indeed, the molar ratio was highest during midadolescence, when both IGF-I and IGFBP-3 were at their zeniths. Serum IGFBP-1 was significantly higher in adolescent compared with adult females. However, estradiol replacement significantly elevated serum IGFBP-1 in adult, but not adolescent, females, abolishing the age differences observed under no estradiol conditions. Serum GH was significantly higher in adolescent compared with adult females; levels in juvenile animals were intermediate. Replacement with estradiol significantly elevated serum GH in adolescent and adult females, particularly in females supplemented with IGF-I. In contrast, estradiol had no effect on serum GH during the juvenile phase. Supplementation with IGF-I significantly dampened the response to GHRH in young and fully adult females, but not in juvenile animals. However, estradiol replacement restored the response to GHRH in these adult, IGF-I-supplemented females. These data indicate that in the absence of any ovarian influence, the decline in serum IGF-I and IGFBP-3 begins in postpubertal, young adult females and is not necessarily a consequence of old age. Furthermore, there is an age-dependent uncoupling of estradiol regulation of the GH-IGF-I axis, as estradiol stimulates GH and IGFBP-3 at all ages but increases serum IGF-I only during adolescent and decreases IGF-I in postpubertal, young adult females. Furthermore, IGF-I has a greater suppressive effect on GH secretion with advancing age, an effect reversed by estradiol replacement. These data suggest that the deficits in the GH-IGF-I axis observed in aged individuals may reflect a continuation of the regulatory changes that begin in young adult females.
对雌性恒河猴生长激素-胰岛素样生长因子I(IGF-I)轴的发育变化进行了评估,以验证以下假设:从青春期到成年期,雌二醇对IGF-I分泌以及IGF-I与IGF结合蛋白-3(IGFBP-3)的摩尔比具有不同的调节作用,并且面对IGF-I对生长激素(GH)增强的负反馈抑制,雌二醇能够重建GH分泌。将成年去卵巢雌性与18至36月龄的去卵巢青春期雌性进行比较,这一时期涵盖了幼年期直至预期的首次排卵年龄。在整个研究期间,对成年(n = 5)和青春期雌性(n = 5)的一个亚组持续给予人IGF-I(110微克/千克·天,皮下注射),并与年龄匹配的未治疗成年动物(n = 5)和青春期动物(n = 6)进行比较。为了进一步了解IGF-I如何影响GH-IGF-I轴,评估了成年雌性以及处于发育阶段的两个年龄的雌性对IGF-I(100微克/千克,皮下注射)的急性反应。此外,所有雌性定期接受雌二醇(4微克/千克·天)治疗,以评估从青春期到成年期对GH-IGF-I轴参数的影响。最后,在成年雌性以及18和24月龄的青春期雌性处于无雌二醇和雌二醇替代状态时,评估对生长激素释放激素(GHRH,1.0微克/千克,静脉注射)的反应。在没有雌二醇替代的情况下,血清IGF-I和IGFBP-3在整个青春期显著增加,然后从青春期后期到成年期下降。补充IGF-I导致所有年龄的血清IGF-I和IGFBP-3浓度显著增加,尽管对幼年雌性的影响较小。然而,在这些补充动物中,IGF-I和IGFBP-3随年龄的增加和下降情况仍然存在。雌二醇替代在整个青春期显著增加了血清IGF-I和IGFBP-3,即使在补充IGF-I的动物中也是如此。然而,随着从青春期过渡,雌二醇抑制血清IGF-I分泌,但在年轻成年和完全成年雌性中继续增加IGFBP-3。与IGFBP-3相比,IGF-I比例的这种变化导致IGF-I与IGFBP-3的摩尔比随年龄显著下降。实际上该摩尔比在青春期中期最高,此时IGF-I和IGFBP-3均处于峰值。青春期雌性的血清IGFBP-1显著高于成年雌性。然而,雌二醇替代显著提高了成年雌性而非青春期雌性的血清IGFBP-1,消除了在无雌二醇条件下观察到的年龄差异。青春期雌性的血清GH显著高于成年雌性;幼年动物的水平居中。雌二醇替代显著提高了青春期和成年雌性的血清GH,特别是在补充IGF-I的雌性中。相反,雌二醇在幼年期对血清GH没有影响。补充IGF-I显著减弱了年轻和完全成年雌性对GHRH的反应,但对幼年动物没有影响。然而,雌二醇替代恢复了这些成年、补充IGF-I的雌性对GHRH的反应。这些数据表明,在没有任何卵巢影响的情况下,血清IGF-I和IGFBP-3的下降始于青春期后的年轻成年雌性,不一定是衰老的结果。此外,雌二醇对GH-IGF-I轴的调节存在年龄依赖性解偶联,因为雌二醇在所有年龄都刺激GH和IGFBP-3,但仅在青春期增加血清IGF-I,并在青春期后的年轻成年雌性中降低IGF-I。此外,随着年龄增长,IGF-I对GH分泌的抑制作用更大,而雌二醇替代可逆转这种作用。这些数据表明,在老年个体中观察到的GH-IGF-I轴缺陷可能反映了始于年轻成年雌性的调节变化的延续。